These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19053054)

  • 1. Relationship between various clinical outcome assessments in patients with blepharospasm.
    Jankovic J; Kenney C; Grafe S; Goertelmeyer R; Comes G
    Mov Disord; 2009 Feb; 24(3):407-13. PubMed ID: 19053054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
    Saad J; Gourdeau A
    J Neuroophthalmol; 2014 Sep; 34(3):233-6. PubMed ID: 24739994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.
    Jankovic J; Comella C; Hanschmann A; Grafe S
    Mov Disord; 2011 Jul; 26(8):1521-8. PubMed ID: 21520284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm.
    Wabbels B; Reichel G; Fulford-Smith A; Wright N; Roggenkämper P
    J Neural Transm (Vienna); 2011 Feb; 118(2):233-9. PubMed ID: 21161715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation.
    Thussu A; Barman CR; Prabhakar S
    Neurol India; 1999 Sep; 47(3):206-9. PubMed ID: 10514580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm.
    Fezza J; Burns J; Woodward J; Truong D; Hedges T; Verma A
    J Neurol Sci; 2016 Aug; 367():56-62. PubMed ID: 27423565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The blepharospasm disability scale: an instrument for the assessment of functional health in blepharospasm.
    Lindeboom R; De Haan R; Aramideh M; Speelman JD
    Mov Disord; 1995 Jul; 10(4):444-9. PubMed ID: 7565824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment.
    Quagliato EM; Carelli EF; Viana MA
    Clin Neuropharmacol; 2010; 33(1):27-31. PubMed ID: 20124784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled, crossover clinical trial of super blue-green algae in patients with essential blepharospasm or Meige syndrome.
    Vitale S; Miller NR; Mejico LJ; Perry JD; Medura M; Freitag SK; Girkin C
    Am J Ophthalmol; 2004 Jul; 138(1):18-32. PubMed ID: 15234278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial.
    Truong D; Comella C; Fernandez HH; Ondo WG;
    Parkinsonism Relat Disord; 2008; 14(5):407-14. PubMed ID: 18325821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact on quality of life of botulinum toxin treatments for essential blepharospasm.
    MacAndie K; Kemp E
    Orbit; 2004 Dec; 23(4):207-10. PubMed ID: 15590520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm.
    Ochudlo S; Bryniarski P; Opala G
    Parkinsonism Relat Disord; 2007 Dec; 13(8):505-8. PubMed ID: 17543569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin type A purified neurotoxin complex for the treatment of blepharospasm: a dose-response study measuring eyelid force.
    Iwashige H; Nemeto Y; Takahashi H; Maruo T
    Jpn J Ophthalmol; 1995; 39(4):424-31. PubMed ID: 8926651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported benefit from botulinum toxin treatment for essential blepharospasm: using 2 assessment scales.
    Lee RM; Chowdhury HR; Hyer JN; Smith HB; Jones CA
    Ophthalmic Plast Reconstr Surg; 2013; 29(3):196-7. PubMed ID: 23446304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.
    Marchetti A; Magar R; Findley L; Larsen JP; Pirtosek Z; Růzicka E; Jech R; Sławek J; Ahmed F
    Mov Disord; 2005 Aug; 20(8):937-44. PubMed ID: 15810022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.
    Truong DD; Gollomp SM; Jankovic J; LeWitt PA; Marx M; Hanschmann A; Fernandez HH;
    J Neural Transm (Vienna); 2013 Sep; 120(9):1345-53. PubMed ID: 23435927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
    Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relations between nonmotor manifestations and motor disorders in patients with benign essential blepharospasm.
    Zhou Y; Wang W; Lin Z; Lin T; Gong L
    Graefes Arch Clin Exp Ophthalmol; 2023 Dec; 261(12):3615-3623. PubMed ID: 37341835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.